Avails Medical awarded $2.5M in CARB-X funding for the development of its rapid antibiotic susceptibility testing device to identify the most effective antibiotic therapy
MENLO PARK, Calif., February 1, 2021 /PRNewswire/ -- Avails Medical, a pioneer in rapid, automated and fully electrical antibiotic susceptibility testing (AST) announced today it was awarded up to $2.5M in…Read More
Avails Medical, a pioneer in automated, accelerated antibiotic susceptibility testing for septic patients announced today the participation of OMRON VENTURES Co., Ltd. in its current equity financing round
MENLO PARK, Calif., March 24, 2020 /PRNewswire/ -- Avails Medical, a pioneer in automated, accelerated antibiotic susceptibility testing (AST) for septic patients announced today the participation of OMRON VENTURES Co., Ltd. in…Read More
Avails Medical announcing eQuant, a novel IVD being developed to allow rapid standardized inoculum generation directly from a positive blood culture
Product integrates to non-rapid commercial AST, antibiotic susceptibility test, systems and dramatically shortens the process. Menlo Park, Calif., Apr. 11th, 2019 (PRESS RELEASE) -- Avails Medical, Inc. (www.availsmedical.com), an in-vitro…Read More
ASM Conference, Chicago, IL June 18-22, 2020
The ASM Program Committee will convene on March 27 to evaluate options for ASM Microbe in response to COVID-19.